Credit: congerdesign / Pixabay.

Digital health company NeuroRPM has received clearance from the US Food and Drug Administration (FDA) for its artificial intelligence (AI)-powered remote monitoring app for Parkinson’s disease.

The NeuroRPM technology monitors the Parkinson’s disease symptoms of bradykinesia, tremor and dyskinesia continuously and passively with AI and the Apple Watch.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With advanced and comprehensive monitoring capabilities for Parkinson’s added to the wearable device, the technology allows the full range of disease symptoms to be tracked on a day-to-day basis.

NeuroRPM president Atila Omer said: “We are thrilled to be on the new frontier of digital health with NeuroRPM. By leveraging the power of Apple Watch, we are transforming the way individuals with Parkinson’s disease understand their health, enabling care providers to make more informed clinical decisions, which will lead to better health outcomes.

“We are honoured to help drive this revolution in healthcare.”

The technology comprises proprietary algorithms that are integrated into an Apple Watch app.

This app passively gathers information during everyday use and helps to continuously monitor symptoms and health metrics for Parkinson’s disease.

Available by prescription, the NeuroRPM technology only uses Apple Watch information that users have chosen to share with the app.

Said to be the culmination of years of studies and technical research, NeuroRPM represents a major advancement in Parkinson’s disease management.

NeuroRPM co-founder and University of Maryland Functional Neurosurgery director Dr Alexander Ksendzovsky said: “This technology will allow for unprecedented insights into the symptoms of Parkinson’s disease including bradykinesia, tremor, and dyskinesia, using critical health and wellness data from Apple Watch.”